{
  "personality": null,
  "timestamp": "2025-10-05T04:30:26.727786",
  "category": "Health",
  "news_summary": "Recent breakthroughs reveal promising advances in cancer treatment, AI-designed antibiotics, and the potential of creative hobbies to slow brain aging at the molecular level.",
  "news_summary_fr": "Des avancées récentes révèlent des progrès prometteurs dans le traitement du cancer, des antibiotiques conçus par l'IA et le potentiel des loisirs créatifs pour ralentir le vieillissement du cerveau au niveau moléculaire.",
  "news_summary_es": "Descubrimientos recientes revelan avances prometedores en el tratamiento del cáncer, antibióticos diseñados por inteligencia artificial y el potencial de las aficiones creativas para frenar el envejecimiento cerebral a nivel molecular.",
  "articles": [
    {
      "title": "Doctors stunned by a cheap drug’s power against colon cancer",
      "summary": "A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. The research, involving over 3,500 patients, is the first randomized study to confirm aspirin’s powerful effect in this context. The findings suggest aspirin could become a widely available, inexpensive precision medicine, reshaping cancer treatment strategies globally.",
      "content": "A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.\n\nEvery year, nearly two million people worldwide are diagnosed with colorectal cancer. Between 20 and 40 percent develop metastases, which makes the disease both more difficult to treat and more deadly.\n\nPrevious observational studies have suggested that aspirin may reduce the risk of certain cancers and possibly also the risk of recurrence after surgery in patients with colorectal cancer harboring mutations in genes within the PIK3 signaling pathway.\n\nThese genes regulate key cellular processes such as growth and division. When mutated, these processes can become dysregulated, leading to uncontrolled cell proliferation and cancer development. However, prior findings have been inconsistent and no randomized clinical trials had previously confirmed the association. To address this gap, the ALASCCA trial was initiated and has now been published in The New England Journal of Medicine.\n\nThe current study included more than 3,500 patients with colon and rectal cancer from 33 hospitals in Sweden, Norway, Denmark, and Finland. Patients whose tumors showed a specific genetic mutation in the PIK3 signaling pathway -- a mutation found in approximately 40 percent of patients -- were randomized to receive either 160 mg of aspirin daily or a placebo for three years after surgery.\n\nFor patients with the genetic mutation in PIK3, the risk of recurrence was reduced by 55 percent in those who received aspirin compared with the placebo group.\n\n\"Aspirin is being tested here in a completely new context as a precision medicine treatment. This is a clear example of how we can use genetic information to personalize treatment and at the same time save both resources and suffering,\" says first author Anna Martling, professor at the Department of Molecular Medicine and Surgery, Karolinska Institutet, and senior consultant surgeon at Karolinska University Hospital.\n\nSo how does aspirin reduce the risk of recurrence of colon and rectal cancer? The researchers believe that the effect is likely due to aspirin acting through several parallel mechanisms - it reduces inflammation, inhibits platelet function and tumor growth. This combination makes the environment less favorable for cancer.\n\n\"Although we do not yet fully understand all the molecular links, the findings strongly support the biological rationale and suggest that the treatment may be particularly effective in genetically defined subgroups of patients,\" says Anna Martling.\n\nThe researchers believe that the results could have global significance and influence treatment guidelines for colon and rectal cancer worldwide. Anna Martling sees the fact that the drug is well established as a major advantage.\n\n\"Aspirin is a drug that is readily available globally and extremely inexpensive compared to many modern cancer drugs, which is very positive,\" says Anna Martling.\n\nThe study was funded in part by the Swedish Research Council and the Swedish Cancer Society. The researchers state that there are no conflicts of interest.\n\nFacts: What is aspirin?\n\nAspirin is a medicine that contains acetylsalicylic acid, a substance that relieves pain, fever, and inflammation. It belongs to the group of NSAIDs (non-steroidal anti-inflammatory drugs). The effect usually occurs within 30 minutes. In low doses, it is also used to prevent blood clots.\n\nCommon side effects include stomach problems and increased bleeding tendency. People with stomach ulcers, bleeding disorders, or asthma should avoid aspirin. Aspirin is available over the counter in higher doses, but should be used with caution, especially in combination with other blood-thinning agents or alcohol.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251003033921.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-04",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a significant, large-scale randomized clinical trial demonstrating that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. This breakthrough has broad global health implications, offering an inexpensive, widely available precision medicine that could reshape cancer treatment and improve survival for millions worldwide. The study is well-detailed, focused, and presents a clear positive real-world impact.",
      "category": "Health",
      "personality_title": "Low-dose aspirin cuts colon cancer return risk by half in genetic trial",
      "personality_presentation": "**Context** – Colon and rectal cancer affect nearly two million people each year worldwide. For many, the cancer can come back after surgery, especially in those with certain genetic changes in their tumors. Scientists have long wondered if aspirin, a common medicine, could help prevent this return of cancer.\n\n**What happened** – A research team from Sweden led a large clinical trial called ALASCCA, involving over 3,500 patients from Nordic countries. They gave some patients a low dose of aspirin (160 mg daily) and others a placebo for three years after surgery. The study focused on patients whose tumors had a specific mutation in the PIK3 gene pathway, found in about 40% of cases.\n\n**Impact** – The trial showed that patients with this genetic mutation who took aspirin had a 55% lower chance of cancer coming back compared to those who did not take aspirin. This is the first randomized study to prove aspirin’s strong effect in preventing cancer recurrence for this group. Aspirin works by reducing inflammation and stopping cancer cells from growing, making the body less welcoming to cancer.\n\n**What’s next step** – Researchers hope these findings will change treatment guidelines worldwide, making aspirin a common, affordable option for colon and rectal cancer patients with this genetic mutation. More studies may explore how aspirin works and test it in other cancer types.\n\n**One-sentence takeaway** – A simple, low-cost aspirin treatment can cut the risk of colon and rectal cancer returning by half in patients with a certain genetic mutation, offering a new way to improve cancer care globally.",
      "personality_title_fr": "L’aspirine à faible dose réduit de moitié le risque de récidive du cancer du côlon",
      "personality_presentation_fr": "**Contexte** – Le cancer du côlon et du rectum touche près de deux millions de personnes chaque année dans le monde. Pour beaucoup, le cancer peut revenir après une opération, surtout chez ceux dont les tumeurs ont certaines mutations génétiques. Les scientifiques se demandaient depuis longtemps si l’aspirine, un médicament courant, pouvait aider à empêcher ce retour.\n\n**Ce qui s’est passé** – Une équipe de recherche suédoise a mené un grand essai clinique appelé ALASCCA, avec plus de 3 500 patients dans les pays nordiques. Certains patients ont reçu une faible dose d’aspirine (160 mg par jour), d’autres un placebo, pendant trois ans après l’opération. L’étude s’est concentrée sur les patients dont les tumeurs présentaient une mutation spécifique dans le gène PIK3, présente dans environ 40 % des cas.\n\n**Impact** – L’essai a montré que les patients avec cette mutation qui prenaient de l’aspirine avaient 55 % moins de risque que le cancer revienne, comparé à ceux qui ne prenaient pas d’aspirine. C’est la première étude randomisée qui prouve l’effet puissant de l’aspirine pour prévenir la récidive chez ce groupe. L’aspirine agit en réduisant l’inflammation et en arrêtant la croissance des cellules cancéreuses, rendant le corps moins favorable au cancer.\n\n**Prochaine étape** – Les chercheurs espèrent que ces résultats feront changer les recommandations de traitement dans le monde, pour que l’aspirine devienne une option courante et peu coûteuse pour les patients atteints de cancer du côlon et du rectum avec cette mutation génétique. D’autres études pourraient explorer comment l’aspirine agit et la tester sur d’autres types de cancers.\n\n**Résumé en une phrase** – Un traitement simple et peu coûteux à base d’aspirine peut réduire de moitié le risque de récidive du cancer du côlon et du rectum chez les patients avec une mutation génétique spécifique, offrant une nouvelle voie pour améliorer les soins contre le cancer à l’échelle mondiale.",
      "personality_title_es": "La aspirina en baja dosis reduce a la mitad el riesgo de recaída del cáncer de colon",
      "personality_presentation_es": "**Contexto** – El cáncer de colon y recto afecta a casi dos millones de personas cada año en todo el mundo. Para muchos, el cáncer puede regresar después de la cirugía, especialmente en quienes tienen ciertos cambios genéticos en sus tumores. Los científicos se habían preguntado si la aspirina, un medicamento común, podría ayudar a prevenir esta recaída.\n\n**Qué pasó** – Un equipo de investigación sueco dirigió un gran ensayo clínico llamado ALASCCA, con más de 3.500 pacientes de países nórdicos. A algunos pacientes se les dio una baja dosis de aspirina (160 mg diarios) y a otros un placebo durante tres años después de la cirugía. El estudio se centró en pacientes cuyos tumores tenían una mutación específica en el gen PIK3, presente en alrededor del 40 % de los casos.\n\n**Impacto** – El ensayo mostró que los pacientes con esta mutación genética que tomaron aspirina tuvieron un 55 % menos de riesgo de que el cáncer regresara, en comparación con quienes no tomaron aspirina. Este es el primer estudio aleatorizado que demuestra el fuerte efecto de la aspirina para prevenir la recaída en este grupo. La aspirina funciona reduciendo la inflamación y deteniendo el crecimiento de las células cancerosas, haciendo que el cuerpo sea menos favorable para el cáncer.\n\n**Próximo paso** – Los investigadores esperan que estos hallazgos cambien las guías de tratamiento en todo el mundo, haciendo que la aspirina sea una opción común y económica para pacientes con cáncer de colon y recto que tengan esta mutación genética. Se podrían realizar más estudios para entender mejor cómo funciona la aspirina y probarla en otros tipos de cáncer.\n\n**Conclusión en una frase** – Un tratamiento simple y económico con aspirina puede reducir a la mitad el riesgo de recaída del cáncer de colon y recto en pacientes con una mutación genética específica, ofreciendo una nueva forma de mejorar el cuidado del cáncer en todo el mundo.",
      "image_url": "public/images/news_image_Doctors-stunned-by-a-cheap-drugs-power-against-col.png",
      "image_prompt": "A detailed, warm painting of a glowing aspirin tablet gently resting beside a stylized DNA double helix strand entwined with a subtle, calming network of cellular pathways, all set against a soft background of intertwined colon and rectal tissue patterns rendered in natural, muted tones."
    },
    {
      "title": "This “chaos enzyme” may hold the key to stopping cancer spread",
      "summary": "A Weill Cornell Medicine team has found that triple-negative breast cancer depends on the enzyme EZH2 to spread. By silencing key genes, EZH2 drives chaotic cell divisions and fuels metastasis. Blocking EZH2 restored stability and prevented cancer cells from traveling to distant organs. This discovery opens the door to new therapies that may finally tame this aggressive disease.",
      "content": "Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from spreading. Researchers have discovered that an enzyme called EZH2 drives TNBC cells to divide abnormally, which enables them to relocate to distant organs. The preclinical study also found drugs that block EZH2 could restore order to dividing cells and thwart the spread of TNBC cells.\n\n\"Metastasis is the main reason patients with triple negative breast cancer face poor survival odds,\" said senior author Dr. Vivek Mittal, Ford-Isom Research Professor of Cardiothoracic Surgery and member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. \"Our study suggests a new therapeutic approach to block metastasis before it starts and help patients overcome this deadly cancer.\"\n\nThe findings, published Oct. 2 in Cancer Discovery, challenge the popular notion that cancer treatments should boost cell division errors already occurring in tumor cells beyond the breaking point to induce cell death. When normal cells divide, the chromosomes -- DNA \"packages\" carrying genes -- are duplicated and split evenly into two daughter cells. This process goes haywire in many cancer cells, leading to chromosomal instability: too many, too few, or jumbled chromosomes in multiple daughter cells.\n\n\"I find the attempt to drive cancer cells over the edge with more chromosomal instability a little concerning because if you don't reach the right level, it may paradoxically lead to aggressive disease,\" Dr. Mittal said. \"Instead, our findings suggest that restoring order to cell division by targeting EZH2 can stop them from spreading.\"\n\nFirst author Dr. Shelley Yang Bai began this work as a graduate student and is now a postdoctoral associate with Dr. Mittal in cardiothoracic surgery at Weill Cornell Medicine. Dr. Samuel Bakhoum, who was at Memorial Sloan Kettering Cancer Center at the time, co-led this study.\n\nLinking Epigenetics and Metastasis\n\nAbout 5% of cells in a TNBC primary tumor are highly likely to metastasize, and these cells have unique features such as different metabolism, increased chromosomal instability and altered epigenetics -- modifications to DNA or its associated proteins that do not directly change the genetic code.\n\nDr. Mittal's team found a suspicious culprit that could be triggering metastasis in these particular cancer cells: EZH2. This protein normally modifies how DNA is packaged in cells. But cancers often hijack EZH2 by increasing its production. In TNBC, this overproduction leads to the silencing of key genes needed for chromosomes to segregate properly during cell division and to rampant errors.\n\nWhen analyzing data from breast cancer patients, Dr. Bai found that patients with higher levels of EZH2 also had tumor cells with more chromosomal alterations. This provided clues for further lab experiments. While inhibiting EZH2 with tazemetostat, an FDA-approved drug to treat certain cancers, reduced chromosomal instability in cell lines, boosting EZH2 levels genetically increased errors in cell division.\n\nFurthermore, mouse models with elevated EZH2 and chromosomal instability in primary tumors showed increased lung metastases compared to tumors lacking EZH2, confirming a direct link between EZH2 levels, chromosomal instability and metastasis. But how was EZH2 driving instability?\n\nChromosomal Chaos\n\nThe team discovered that EZH2 silences the tankyrase 1 gene, which normally ensures the chromosome-separating machinery works properly during cell division. This triggers a chain reaction -- the decrease in tankyrase 1 causes another protein called CPAP to build up excessively. This prompts the cell's centrosomes -- structures that pull chromosomes apart -- to multiply uncontrollably, leading to faulty divisions into three or more daughter cells.\n\nThe team showed that inhibiting EZH2 restored balance, significantly reducing metastasis in preclinical models. \"For the first time, we have linked EZH2, which is an epigenetic regulator, with chromosomal instability in a mechanistic fashion,\" Dr. Bai said.\n\nEZH2 inhibitors may be the first drugs that can suppress chromosomal instability directly. \"This study provides a promising new approach to treating triple-negative breast cancer by targeting the root cause of metastases,\" said Dr. Magdalena Plasilova, associate professor of clinical surgery (pending appointment at rank), a surgical oncologist at NewYork-Presbyterian/Weill Cornell Medical Center and an author on the study. \"I see firsthand the devastating impact of metastases on patients, and this offers hope for improved outcomes and survival rates.\"\n\nWhile Tazemetostat could be repurposed as a treatment for TNBC, other drugs might have similar or better effects. \"Our discovery opens the door for clinical trials to test EZH2 inhibitors in high-risk breast cancer and potentially other cancers that are also marked by chromosomal instability, such as lung adenocarcinoma,\" said Dr. Mittal, who is also a member of the Englander Institute of Precision Medicine at Weill Cornell. Currently, he is planning collaborations to conduct safety tests in a clinical trial.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251004092858.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-04",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant scientific discovery identifying the enzyme EZH2 as a driver of metastasis in triple-negative breast cancer and demonstrates that blocking this enzyme can prevent cancer spread. This finding has broad implications for developing new therapies that could improve survival rates for patients with a highly aggressive and difficult-to-treat cancer type. The study is detailed, focused on a single breakthrough, and highlights potential clinical applications, making it genuinely inspiring good news with meaningful real-world impact.",
      "category": "Health",
      "personality_title": "Scientists find enzyme that helps stop the spread of aggressive breast cancer",
      "personality_presentation": "**Context** – Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer that is hard to treat. One big problem is that it spreads quickly to other parts of the body, making it deadly. Scientists have been looking for new ways to stop this spread.\n\n**What happened** – Researchers at Weill Cornell Medicine discovered that an enzyme called EZH2 plays a key role in helping TNBC cells divide in a messy way. This messy division allows cancer cells to travel to other organs. The team found that blocking EZH2 with drugs could fix the cell division process and stop the cancer cells from spreading. They tested this in lab experiments and in mice.\n\n**Impact** – This is important because it shows a new way to fight TNBC by targeting EZH2. Instead of trying to make cancer cells more unstable, which can sometimes make the disease worse, this approach restores order in how cells divide. It could lead to better treatments that stop cancer from spreading, which is the main cause of death in TNBC patients.\n\n**What’s next step** – The researchers plan to start clinical trials to test EZH2-blocking drugs in patients with TNBC. They also want to explore if this approach could work for other cancers with similar problems in cell division, like certain lung cancers.\n\n**One-sentence takeaway** – Blocking the enzyme EZH2 may stop aggressive breast cancer cells from spreading, offering a new way to treat this deadly disease.",
      "personality_title_fr": "Les scientifiques découvrent une enzyme qui aide à stopper la propagation d’un cancer du sein agressif",
      "personality_presentation_fr": "**Contexte** – Le cancer du sein triple négatif (TNBC) est une forme très agressive de cancer du sein, difficile à traiter. Le principal problème est qu’il se propage rapidement dans d’autres parties du corps, ce qui le rend mortel. Les chercheurs cherchent de nouvelles façons d’arrêter cette propagation.\n\n**Ce qui s’est passé** – Des chercheurs de Weill Cornell Medicine ont découvert qu’une enzyme appelée EZH2 joue un rôle clé en provoquant une division désordonnée des cellules TNBC. Cette division désordonnée permet aux cellules cancéreuses de migrer vers d’autres organes. Ils ont trouvé qu’en bloquant EZH2 avec des médicaments, ils pouvaient corriger la division cellulaire et empêcher la propagation du cancer. Ils ont testé cela en laboratoire et sur des souris.\n\n**Impact** – Cette découverte est importante car elle montre une nouvelle façon de combattre le TNBC en ciblant EZH2. Au lieu d’augmenter l’instabilité des cellules cancéreuses, ce qui peut aggraver la maladie, cette méthode remet de l’ordre dans la division cellulaire. Cela pourrait permettre de meilleurs traitements pour stopper la propagation du cancer, principale cause de décès chez les patients.\n\n**Prochaine étape** – Les chercheurs prévoient des essais cliniques pour tester les médicaments bloquant EZH2 chez les patients atteints de TNBC. Ils veulent aussi voir si cette méthode fonctionne pour d’autres cancers avec des problèmes similaires de division cellulaire, comme certains cancers du poumon.\n\n**Résumé en une phrase** – Bloquer l’enzyme EZH2 pourrait empêcher la propagation des cellules cancéreuses agressives du sein, offrant une nouvelle voie de traitement de cette maladie mortelle.",
      "personality_title_es": "Científicos encuentran una enzima que ayuda a detener la propagación del cáncer de mama agresivo",
      "personality_presentation_es": "**Contexto** – El cáncer de mama triple negativo (TNBC) es una forma muy agresiva y difícil de tratar. Un gran problema es que se extiende rápidamente a otras partes del cuerpo, lo que lo hace mortal. Los científicos buscan nuevas formas de detener esta propagación.\n\n**Qué pasó** – Investigadores de Weill Cornell Medicine descubrieron que una enzima llamada EZH2 es clave para que las células TNBC se dividan de manera desordenada. Esta división desordenada permite que las células cancerosas viajen a otros órganos. Encontraron que al bloquear EZH2 con medicamentos, podían corregir la división celular y evitar que el cáncer se extendiera. Lo probaron en laboratorios y en ratones.\n\n**Impacto** – Esto es importante porque muestra una nueva forma de combatir el TNBC al atacar EZH2. En lugar de aumentar la inestabilidad celular, lo que a veces empeora la enfermedad, este método restaura el orden en la división celular. Podría llevar a mejores tratamientos que detengan la propagación del cáncer, la principal causa de muerte en pacientes con TNBC.\n\n**Próximo paso** – Los investigadores planean iniciar ensayos clínicos para probar medicamentos que bloquean EZH2 en pacientes con TNBC. También quieren ver si esta estrategia funciona en otros tipos de cáncer con problemas similares en la división celular, como algunos cánceres de pulmón.\n\n**Conclusión en una frase** – Bloquear la enzima EZH2 puede detener la propagación de células de cáncer de mama agresivo, ofreciendo una nueva forma de tratar esta enfermedad mortal.",
      "image_url": "public/images/news_image_This-chaos-enzyme-may-hold-the-key-to-stopping-can.png",
      "image_prompt": "A detailed painting of a delicate cellular landscape where a calm, glowing enzyme figure gently untangles and organizes a chaotic cluster of swirling, multicolored chromosomes, symbolizing the restoration of order in cell division, set against a soft, natural background of warm earth tones and subtle light."
    },
    {
      "title": "AI has designed thousands of potential antibiotics. Will any work?",
      "summary": "Nature, Published online: 03 October 2025; doi:10.1038/d41586-025-03201-6Machine learning can speed up the discovery of potential antibiotics but challenges remain.",
      "content": "Credit: Chris Ratcliffe/Bloomberg via Getty\n\nResearchers are turning to artificial intelligence (AI) to help design the next generation of antibiotics to combat rising antimicrobial resistance. In minutes, AI can design thousands of chemical compounds with potential antibacterial properties, although there are hurdles to overcome before the first of these medicines can be tested in people.\n\nLast week, the US Centers for Disease Control reported that rates of dangerous bacterial infections surged by 69% between 2019 and 2023. Enterobacterales bacteria, also called 'nightmare bacteria', are particularly difficult to treat with existing antibiotics. Globally, 1.1 million deaths a year are linked to bacterial resistance to antimicrobial drugs.\n\nThe standard method of antibiotic discovery involves going into nature and sifting through dirt to find antibacterial compounds, says César de la Fuente, a machine biologist at the University of Pennsylvania, Philadelphia. “That’s really painstaking work that relies on trial and error, and it can take many years,” he adds. His team has been using AI to discover antibiotics for about a decade. The whole process of discovering a candidate, creating it in the laboratory and testing it in cells can be done “within a week or two”, he adds.\n\nMost AI-designed antibiotics are still in early development. None has yet been tested in humans.\n\nAI-designed drugs\n\nMachine learning and generative AI (genAI) can speed up the process. De la Fuente and his team train machine-learning algorithms by showing them compounds that can harm bacteria, and others that cannot. The AI designs antibiotics by looking for fragments of proteins with antibacterial properties in data sets that it has not seen before. These include the proteomes — the complete set of proteins that an organism can express — of animals, plants and bacteria.\n\nGenAI algorithms — similar to the AI used in chatbots or image generators — are trained on the same data but designed to create new compounds. Earlier this month, de la Fuente and his team reported that their genAI model designed 50,000 peptides, or short chains of amino acids, that have antimicrobial properties and can destroy pathogens1. A deep-learning model then ranked these on the basis of how effective it thinks they might be at killing several bacteria types. Of the top 46 synthesized peptides, about 35 killed at least one bacterial strain in a dish, and most were not toxic to human embryonic kidney cells. The top two candidates were then tested and found to be effective against Acinetobacter baumannii in mouse models.\n\nChallenges ahead\n\nBut making AI-designed antibiotics in the lab can be challenging. For example, bioengineer Jim Collins, at the Massachusetts Institute of Technology in Cambridge, has found that some AI-designed antibiotics are chemically unstable and cannot be synthesized. Others take too many steps to make and would be too costly and time-consuming to produce commercially.",
      "url": "https://www.nature.com/articles/d41586-025-03201-6",
      "source": "Nature",
      "published": "2025-10-05",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific advancement where AI accelerates the discovery of potential new antibiotics, addressing the critical global health threat of antimicrobial resistance. This breakthrough has broad implications for public health worldwide, offering hope for faster development of effective treatments against dangerous bacterial infections. The article provides detailed context on the AI methods used, the scale of discovery, and the challenges ahead, demonstrating substantive progress in a crucial area of medicine.",
      "category": "Health",
      "personality_title": "AI speeds up discovery of thousands of new antibiotic candidates",
      "personality_presentation": "**Context** – Antibiotic resistance is a growing problem worldwide, causing more infections that are hard to treat. Traditional methods to find new antibiotics involve searching natural sources and testing many compounds, which takes years.\n\n**What happened** – Researchers used artificial intelligence (AI) to design tens of thousands of potential antibiotics quickly. The AI studied protein data from animals, plants, and bacteria to create new compounds. In tests, many of these AI-designed compounds were able to kill harmful bacteria in lab dishes and some worked in mice.\n\n**Impact** – This method can find new antibiotic candidates much faster than before, which is important because dangerous bacteria are becoming harder to fight. For example, the AI found 50,000 peptides, and several showed strong ability to kill bacteria without harming human cells.\n\n**What's next step** – Scientists still need to solve challenges like making these compounds stable and affordable to produce. None of the AI-designed antibiotics have been tested in people yet, so more research and development are needed before they can become new medicines.\n\n**One-sentence takeaway** – AI is helping scientists discover many new antibiotic candidates faster than ever, offering a promising path to fight resistant bacteria in the future.",
      "personality_title_fr": "L'IA accélère la découverte de milliers de nouveaux candidats antibiotiques",
      "personality_presentation_fr": "**Contexte** – La résistance aux antibiotiques est un problème croissant dans le monde, provoquant des infections de plus en plus difficiles à soigner. Les méthodes traditionnelles pour trouver de nouveaux antibiotiques consistent à chercher dans la nature et à tester de nombreux composés, ce qui prend des années.\n\n**Ce qui s'est passé** – Des chercheurs ont utilisé l'intelligence artificielle (IA) pour concevoir rapidement des dizaines de milliers de potentiels antibiotiques. L'IA a étudié des données sur les protéines d'animaux, de plantes et de bactéries pour créer de nouveaux composés. Lors des tests, plusieurs de ces composés conçus par l'IA ont tué des bactéries nocives en laboratoire et certains ont fonctionné chez la souris.\n\n**Impact** – Cette méthode permet de trouver des candidats antibiotiques beaucoup plus rapidement, ce qui est important car les bactéries dangereuses deviennent plus résistantes. Par exemple, l'IA a trouvé 50 000 peptides, dont plusieurs ont montré une forte capacité à tuer des bactéries sans nuire aux cellules humaines.\n\n**Prochaine étape** – Les scientifiques doivent encore résoudre des problèmes comme la stabilité et le coût de production de ces composés. Aucun antibiotique conçu par l'IA n'a encore été testé sur des humains, donc d'autres recherches sont nécessaires avant qu'ils puissent devenir des médicaments.\n\n**En résumé** – L'IA aide les scientifiques à découvrir plus vite que jamais de nombreux nouveaux candidats antibiotiques, ouvrant une voie prometteuse pour combattre les bactéries résistantes à l'avenir.",
      "personality_title_es": "La IA acelera el descubrimiento de miles de nuevos candidatos a antibióticos",
      "personality_presentation_es": "**Contexto** – La resistencia a los antibióticos es un problema creciente en todo el mundo, causando infecciones cada vez más difíciles de tratar. Los métodos tradicionales para encontrar nuevos antibióticos implican buscar en la naturaleza y probar muchos compuestos, lo que lleva años.\n\n**Qué pasó** – Investigadores usaron inteligencia artificial (IA) para diseñar rápidamente decenas de miles de posibles antibióticos. La IA estudió datos de proteínas de animales, plantas y bacterias para crear nuevos compuestos. En pruebas, muchos de estos compuestos diseñados por IA lograron matar bacterias dañinas en laboratorio y algunos funcionaron en ratones.\n\n**Impacto** – Este método puede encontrar candidatos a antibióticos mucho más rápido que antes, lo que es importante porque las bacterias peligrosas se están volviendo más resistentes. Por ejemplo, la IA encontró 50,000 péptidos, y varios mostraron gran capacidad para matar bacterias sin dañar células humanas.\n\n**Próximo paso** – Los científicos aún deben resolver desafíos como hacer que estos compuestos sean estables y baratos de producir. Ningún antibiótico diseñado por IA ha sido probado en humanos, por lo que se necesita más investigación antes de que puedan convertirse en medicamentos.\n\n**Conclusión en una frase** – La IA está ayudando a los científicos a descubrir muchos nuevos candidatos a antibióticos más rápido que nunca, ofreciendo un camino prometedor para combatir bacterias resistentes en el futuro.",
      "image_url": "public/images/news_image_AI-has-designed-thousands-of-potential-antibiotics.png",
      "image_prompt": "An intricate, warm-toned painting of a glowing, stylized DNA helix intertwined with luminous peptide chains gently encircling and neutralizing abstract, darkened bacterial shapes shaped like tangled knots, set against a soft, neutral background that evokes a laboratory environment without showing any humans or machines."
    },
    {
      "title": "Creative hobbies could slow brain ageing at the molecular level",
      "summary": "Nature, Published online: 03 October 2025; doi:10.1038/d41586-025-03197-zTo keep the mind young, dance the tango.",
      "content": "The tango’s complexity might make it particularly good for keeping the brain young.Credit: Tempura/Getty\n\nWhether it’s dancing the tango or playing the guitar, engaging in a creative pastime can slow brain ageing, according to a study of dancers, musicians, artists and video game players from multiple countries.\n\nThe analysis used brain clocks — models that measure the difference between a person’s chronological age and the age their brain appears to be — to assess whether creative activities help to maintain neurological youth. In brain regions that are most susceptible to ageing, engaging in creative activities increased connections with different areas of the brain. Although experts had ‘younger’ brains than their less-experienced counterparts did, even learning a creative skill from scratch had an anti-ageing effect on the brain.\n\nThe findings were published on 3 October in Nature Communications1.\n\nSong and dance\n\nPrevious studies suggest that engaging in creative activities can help to keep the brain young and foster emotional well-being. But few have investigated the biological basis of these brain benefits or what drives them, says study co-author Agustín Ibáñez, a neuroscientist at Adolfo Ibáñez University in Santiago, Chile. “There is really poor mechanistic evidence,” he says.\n\nHow fast are you ageing? Ordinary brain scans reveal the pace To address this gap, Ibáñez and his colleagues created brain clocks using neuroimaging data of brain activity taken from 1,240 participants across 10 countries. These machine-learning models used functional connectivity, a measure of how brain regions work together, to estimate brain age. The researchers then applied their brain clocks to 232 tango dancers, musicians, visual artists and video game players of different ages and experience levels to calculate their ‘brain age gap’ — the difference between their predicted brain age and their actual age.\n\nOverall, all four creative pursuits seemed to delay brain ageing. The more skilled and experienced participants were at their chosen activity, the slower their brain aged. This anti-ageing effect was strongest in expert tango dancers, whose brains were, on average, seven years younger than their chronological age. Tango’s cognitively demanding mix of complex movement sequences, coordination and planning makes it a particularly good activity for keeping the brain young, says Ibáñez.\n\nNext, the researchers built a brain map to assess whether creativity has a protective effect on areas that are particularly vulnerable to ageing. They found that creativity had the greatest impact on the frontoparietal region, which controls various functions, including working memory and decision-making. This region is one of the most susceptible areas to age-related decline. In experienced participants, brain connections were notably strong in areas involved in movement control, coordination and rhythm, among others.",
      "url": "https://www.nature.com/articles/d41586-025-03197-z",
      "source": "Nature",
      "published": "2025-10-05",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a scientific study showing that engaging in creative hobbies like tango dancing, playing music, or art can slow brain ageing at a molecular level, providing a measurable, positive impact on neurological health. The study is broad in scope, involving multiple countries and many participants, and offers detailed mechanistic insights into brain function and ageing. This represents a meaningful breakthrough in understanding how lifestyle activities can preserve brain health and cognitive function, which is highly relevant to the general public.",
      "category": "Health",
      "personality_title": "Creative hobbies like tango dance can slow brain ageing, study finds",
      "personality_presentation": "**Context** – Scientists have been curious about how creative activities like dancing, playing music, or making art affect the brain as people get older. While previous research suggested these hobbies might keep the brain young, it was unclear exactly how they worked at the biological level.\n\n**What happened** – A team of researchers studied 1,240 people from 10 countries using brain scans and special computer models called brain clocks. These models compare the brain’s actual age to a person’s real age by measuring how different brain regions connect and work together. They then looked at 232 people who were tango dancers, musicians, artists, or video game players to see if their creative skills helped keep their brains younger.\n\n**Impact** – The study found that all creative hobbies helped slow down brain ageing, especially in the frontoparietal region, which controls memory and decision-making and usually ages quickly. The most impressive results were from expert tango dancers, whose brains appeared about seven years younger than their actual age. This shows that even starting a creative hobby later in life can protect the brain and improve how different brain areas communicate.\n\n**What’s next step** – Researchers plan to explore how these brain changes happen and whether other types of creative activities have similar effects. They also hope to find ways to use this knowledge to help people maintain brain health as they grow older.\n\n**One-sentence takeaway** – Taking part in creative activities like tango dancing or playing music can slow brain ageing by strengthening important brain connections.\n",
      "personality_title_fr": "Les loisirs créatifs comme le tango ralentissent le vieillissement du cerveau, selon une étude",
      "personality_presentation_fr": "**Contexte** – Les scientifiques s’intéressent à la façon dont les activités créatives comme la danse, la musique ou l’art influencent le cerveau en vieillissant. Des recherches précédentes suggéraient que ces loisirs pouvaient garder le cerveau jeune, mais on ne comprenait pas bien comment cela fonctionnait au niveau biologique.\n\n**Ce qui s’est passé** – Une équipe de chercheurs a étudié 1 240 personnes dans 10 pays à l’aide de scanners cérébraux et de modèles informatiques appelés horloges cérébrales. Ces modèles comparent l’âge réel du cerveau à l’âge chronologique d’une personne en mesurant comment différentes régions du cerveau communiquent. Ils ont ensuite examiné 232 danseurs de tango, musiciens, artistes et joueurs de jeux vidéo pour voir si leurs compétences créatives aidaient à préserver la jeunesse de leur cerveau.\n\n**Impact** – L’étude a montré que tous les loisirs créatifs ralentissaient le vieillissement du cerveau, surtout dans la région frontopariétale, qui contrôle la mémoire et la prise de décision et vieillit généralement vite. Les résultats les plus marquants concernent les danseurs de tango experts, dont le cerveau semblait en moyenne sept ans plus jeune que leur âge réel. Cela prouve que même commencer un loisir créatif tard peut protéger le cerveau et améliorer la communication entre ses différentes zones.\n\n**Prochaine étape** – Les chercheurs veulent comprendre comment ces changements cérébraux se produisent et si d’autres activités créatives ont des effets similaires. Ils espèrent aussi utiliser ces connaissances pour aider les gens à garder un cerveau en bonne santé en vieillissant.\n\n**Résumé en une phrase** – Pratiquer des activités créatives comme le tango ou la musique peut ralentir le vieillissement du cerveau en renforçant ses connexions importantes.\n",
      "personality_title_es": "Hobbies creativos como el tango pueden ralentizar el envejecimiento cerebral, revela estudio",
      "personality_presentation_es": "**Contexto** – Los científicos han querido entender cómo actividades creativas como bailar, tocar música o pintar afectan el cerebro a medida que las personas envejecen. Estudios anteriores sugerían que estos pasatiempos podrían mantener el cerebro joven, pero no se sabía exactamente cómo ocurría a nivel biológico.\n\n**Qué pasó** – Un equipo de investigadores estudió a 1,240 personas de 10 países usando escáneres cerebrales y modelos computarizados llamados relojes cerebrales. Estos modelos comparan la edad real del cerebro con la edad cronológica midiendo cómo distintas regiones del cerebro se conectan y trabajan juntas. Luego analizaron a 232 bailarines de tango, músicos, artistas y jugadores de videojuegos para ver si sus habilidades creativas ayudaban a mantener el cerebro más joven.\n\n**Impacto** – El estudio encontró que todos los hobbies creativos ayudaban a retrasar el envejecimiento cerebral, especialmente en la región frontoparietal, que controla la memoria y la toma de decisiones y suele envejecer rápido. Los resultados más fuertes fueron en bailarines expertos de tango, cuyos cerebros parecían siete años más jóvenes que su edad real. Esto muestra que incluso empezar un hobby creativo en la vida adulta puede proteger el cerebro y mejorar la comunicación entre sus áreas.\n\n**Próximo paso** – Los investigadores planean estudiar cómo ocurren estos cambios cerebrales y si otras actividades creativas tienen efectos similares. También esperan usar esta información para ayudar a las personas a mantener la salud cerebral al envejecer.\n\n**Una frase clave** – Participar en actividades creativas como bailar tango o tocar música puede retrasar el envejecimiento del cerebro fortaleciendo sus conexiones importantes.\n",
      "image_url": "public/images/news_image_Creative-hobbies-could-slow-brain-ageing-at-the-mo.png",
      "image_prompt": "A warm, detailed painting of a glowing, abstract human brain composed of intertwined, flowing ribbons symbolizing neural connections, with delicate silhouettes of tango dancers, musicians playing guitar, painters’ brushes, and video game controllers seamlessly woven into the brain’s vibrant frontoparietal region, all rendered in soft, natural earth tones and gentle pastels to evoke creativity and youthful energy."
    }
  ]
}